NeoGenomics is trading 0.7% higher in pre-market at $17.90, versus its October 1 close, with no confirmed company-specific catalyst.
- The supplied price indicates a modest gain, not the 4.1% rise described in the alert headline.
- The surfaced official press release is a September 1 conference notice, not a clear catalyst for the October 2 move.
- Major U.S. indices were reported higher, while healthcare was lower; neither fully explains the move.